Haemonetics Corp. (HAE) Posts Q2 EPS of $0.69, Tops by 4c
More News related to HAE
- Trading Review for Cerus Corp. Issued by Beacon Equity
- Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
- Haemonetics Corp. (HAE) Posts Q2 EPS of $0.69, Tops by 4c
- Haemonetics Reports Double Digit Growth in Earnings for Second Quarter Fiscal 2010
- Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine
More News related to Earnings
- Analysts Bullish on Analog Devices (ADI) Following Q4 Results: AmTech, GC Research Upgrade, Citi Lifts Price Target
- Veeco (VECO) Shares Rally Amid Avian Upgrade
- Raymond James Upgrades AMICAS (AMCS) to Strong Buy
- RBC Upgrades Diamond Rock (DRH) to Outperform, Downgrades Hospitality Properties (HPT) to Sector Perform
- First Global Upgrades NetApp (NTAP) to Outperform; Signs of Business Stabilization & Improvement
Haemonetics Corp. (NYSE: HAE) reports Q2 EPS of $0.69, 4 cents better than the analyst estimate of $0.65. Revenue for the quarter was $157.07 million, which compares to the estimate of $157.84 million.
Related Categories
EarningsStocks Mentioned
+0.24Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
